Embed Size (px)
Citation preview
-19 February 2021
06:00pm - 09:00pm
http://webinar365.in/hcmpl-sabcs/
Contact Us: PALAK AGARWAL
(M)+91 99172 33854
HCMPL
STREAMING PARTNER
Licensed byEndorsed by
Day 2Saturday, 20th February 2021
06:00pm-09:30pmHall A
[email protected] www.bosindia.in
[email protected] www.bosindia.in
Organizing Team
Dr. Meenu WaliaDirector
Department of Medical OncologyMax Super Speciality Hospital, Delhi
(M) +91 9818994001(E) [email protected]
Organizing Secretary
Dr. Vikas TalrejaConsultant,
Department of Medical OncologyRegency Hospital, Kanpur
(M) +91 9769890961(E) [email protected]
Co Organizing Secretary
Dr. Siddharth TurkarMumbai
Day 2 Hall AConvenor
Scientific Program
[email protected] www.bosindia.in
Day 2 || Saturday, 20th February 2021 || 06:00pm-09:30pmHall A
Program Director: Dr. Vikas Talreja | Convenor: Dr. Siddharth Turkar
Time Topic Speaker
05:55pm - 06:00pm Welcome Note Dr. Vikas Talreja, Kanpur
Chairperson Dr. K Pavithran, Kochi
06:00pm - 06:07pm SPD14-05 Genomic profiling and clinical Dr Mansi Sharma, Delhi outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: an exploratory analysis from the phase 3 Impassion1 30 trial
06:07pm - 06:14pm PS13-41 Real-world evidence of platinum-based Dr Rajesh Patidar, chemotherapy for the treatment of BRCA-positive Indore metastatic breast cancer in a cohort of 33,878 women in the United States 06:14pm - 06:21pm SPD14-07 Association between biomarkers and Dr Vineet Govinda response to pembrolizumab in patients with Gupta, Delhi metastatic triple-negative breast cancer (mTNBC): exploratory analysis from KEYNOTE-086
06:21pm - 06:28pm PS17-49 Investigating CDK4/6 inhibition in triple Dr Soumya Surath negative breast cancer Panda, Bhubaneswar
06:28pm - 06:35pm OT-30-01 KEYLYNK-009: A phase 2/3, open-label, Dr Harshvardhan randomized study of pembrolizumab plus olaparib Atreya, Lucknow vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
[email protected] www.bosindia.in
Time Topic Speaker
06:35pm - 06:55pm Panel Discussion: ES4-1 State of the art treatment for metastatic triple negative breast cancer
Moderator Dr. Vivek Agarwala, Kolkata
Panelists Dr Amit Kumar, Patna Dr Bharat Patodia, Mumbai Dr Nirmal Raut, Mumbai Dr. Sameer Khatri, Delhi Dr Mudhasir Ahmed, Delhi
Chairperson Dr. C Sairam, Hyderabad
06:55pm - 07:02pm SPD3-11 A randomized, open-label, phase III trial Dr Sandeep Bairwa, of pertuzumab re-treatment in HER2-positive, Jaipur locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study
07:02pm - 07:09pm SPD3-02 Final analysis of PERTAIN: A Dr Sujay Srinivas, randomized, two-arm, open-label, multicenter Mumbai phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
07:09pm - 07:16pm PS10-53 <b>Treatment Patterns and Clinical Dr Nikhil Pande, Outcomes Among Patients with germline Mumbai BRCA1/2 mutated (<i>gBRCA1/2</i>mut) HER2+ Advanced Breast Cancer (ABC): Results from a US Real-world Study </b>
07:16pm - 07:23pm PS10-44 Termination of trastuzumab-based Dr. Sandeep Goyle, treatment after complete response in HER2-positive Mumbai metastatic breast cancer
07:23pm - 07:30pm PS9-02 Neratinib + capecitabine sustains Dr. Krupa Shankar, health-related quality of life (HRQoL) while Coimbatore improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens
[email protected] www.bosindia.in
Time Topic Speaker
07:30pm - 07:50pm Panel Discussion: ES4-1 State of the art treatment for metastatic Her 2neu+ breast cancer
Moderator Dr Vamshi Krishna, Hyderabad
Panelists Dr Avinash Talele, Indore Dr Uma Dangi, Mumbai Dr Hollis D'souza, Mumbai Dr Mridul Malhotra, Delhi Dr Pratik Chandrani, Mumbai
Chairperson Dr. Bhavesh Parikh, Ahmedabad
07:50pm - 07:57pm SPD2-04 Updated overall survival (OS) results Dr Pritam Kataria, from the phase III MONALEESA-7 trial of Mumbai pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
07:57pm - 08:04pm PS14-03 Ribociclib + letrozole in male patients Dr Rakesh Pinninti, with hormone receptor-positive (HR+), human Hyderabad epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial<b></b>
08:04pm - 08:11pm SPD2-06 Clinical outcomes of alpelisib plus Dr. Naresh Somani, fulvestrant in hormone receptor-positive, human Jaipur epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study
08:11pm - 08:18pm OT-26-01 ABEMACARE: Abemaciclib in Dr Prabhat Bhargava, combination with endocrine therapy as first line Mumbai therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden
[email protected] www.bosindia.in
Time Topic Speaker
08:18pm - 08:25pm OT-36-01 Phase III study of GDC-0077 or Dr Mounika Boppana, placebo (pbo) with palbociclib (P) + fulvestrant (F) Hyderabad in patients with <i>PIK3CA</i>-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)
08:25pm - 08:32pm PS10-16 Real-world efficacy of ribociclib + Dr Shruti Kate, Nasik aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study
08:32pm - 08:39pm 12 year results of anastrozole versus tamoxifen for Dr Ajay Bapna, Jaipur the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ
08:40pm - 09:00pm Panel Discussion: (HR+/Her2neu-) Metastatic Breast Cancer
Moderator Dr Amish Vora, Delhi
Panelists Dr Raajit Chanana, Delhi Dr Jaya Ghosh, Mumbai Dr Lalit Mohan Sharma, Jaipur Dr Rakesh Taran, Indore Dr. Vijay V Sharnangat, Mumbai
09:00pm - 09:15pm Newer options in TNBC-Role of TECENTRIQ in Dr. Meenu Walia, Delhi mTNBC
Guest Lecture
Chairperson Dr. G S Bhattacharyya, Kolkata
09:15pm - 09:30pm Why are we so Late in Treatment of Breast Dr. Stefan Gluck, USA Cancer Using ICI with Chemotherapy?
09:30pm Onwards Closing Remarks Dr. Siddhartha Turkar, Mumbai
HCMPL
STREAMING PARTNER
Contact Us: PALAK AGARWAL
(M)+91 99172 33854
Connect us on:www.hcmpl.com
http://webinar365.in/hcmpl-sabcs/
Scientific Partners
ONCOLOGY
[email protected] www.bosindia.in
![Post SABCS 2014 Wirkmechanismen [Kompatibilitätsmodus] · 2015. 5. 28. · 19.01.2015 1 SABCS 2014 Rudolf Weide Praxisklinik für Hämatologie und Onkologie Koblenz Wirkmechanismus](https://img.pdfslide.us/doc/110x75/60fa1216c8b0ea093936d574/post-sabcs-2014-wirkmechanismen-kompatibilittsmodus-2015-5-28-19012015.jpg)
